Halozyme rises after Phase II pancreatic cancer readout

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.92 (18%) to $12.61 after it reported data from the Phase II HALO 202 study of PEGPH20 to treat pancreatic cancer. The candidate met both of the study's primary endpoints, significantly improving progression-free

Read the full 387 word article

User Sign In